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Abstract
Background/Purpose: Psoriasis is a multisystem disease which has been related to vitamin‑D 
deficiency through chronic inflammation. This psoriasis‑related inflammatory state and vitamin‑D 
deficiency may induce bone mineral density loss. The purpose of this study is to assess the relationship 
of psoriasis with bone mineral density, by comparing psoriatic patients with healthy controls and patients 
with osteopenia/osteoporosis.
Methods: A total of 185 subjects were studied; 58 psoriatic patients who had not been under systemic 
or biological treatment were included. Age, gender, body mass index, phosphocalcic metabolic parameters 
and hip and lumbar (L4) bone mineral density data were collected. These variables were compared with 
those collected in 61 healthy controls and 67 patients with osteopenia/osteoporosis.
Results: Psoriatic patients showed worse hip and lumbar spine bone mineral density levels than 
healthy controls (P = 0.001) and better levels than osteoporotic patients (P < 0.001). Multivariate analysis 
demonstrated a negative association of age and a positive association of body mass index in hip bone 
mineral density in psoriatic patients.
Limitations: The main limitations are those of cross‑sectional studies, such as a lack of follow up period, 
and a male predominance in the psoriatic group, which is corrected employing a multivariate analysis with 
an adjusted model for confounding factors.
Conclusions: Bone mineral density levels in psoriatic patients are situated halfway between healthy 
controls and patients with osteopenia/osteoporosis. In addition, the higher body mass index in patients with 
psoriasis appears to confer a protective effect against further development of lower bone mineral density.
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Introduction
Psoriasis	is	a	chronic	inflammatory	disease	whose	prevalence	
is	estimated	to	be	between	1	and	5%	of	the	world	population.1	
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This	condition	has	been	associated	with	a	higher	prevalence	
of	 metabolic	 syndrome,	 obesity,	 hyperlipidemia,	 diabetes	
mellitus,	 hypertension	 and	 arteriosclerosis.2,3	 These	
comorbidities	seem	to	be	 responsible	 for	 the	 increased	risk	
of	major	cardiovascular	events	in	psoriatic	patients.4	Among	
the	comorbidities	associated	with	psoriasis,	the	association	of	
this	disease	with	vitamin	D	deficiency	is	globally	recognized.
The	 presence	 of	 lower	 levels	 of	 vitamin	 D	 in	 psoriatic	
patients	have	been	related	with	higher	levels	of	cholesterol,	
low‑density	 lipoprotein,	 triglycerides	 and	 glucose.5,6	 The	
reason	 for	 such	 a	 large	 number	 of	 pathologies	 associated	
with	psoriasis	appears	to	lie	in	the	chronic	inflammatory	state	
present	in	psoriatic	patients,	which	has	been	demonstrated	by	
increased	proinflammatory	cytokines	such	as	tumor	necrosis	
factor‑alpha,	interleukin‑12,	interleukin‑23	or	interleukin‑17	
in	these	patients.7,8
Moreover,	 increased	 levels	 of	 C‑reactive	 protein	 have	
been	 found	 in	 psoriatic	 patients,	 as	 well	 as	 low	 levels	 of	
vitamin‑D	metabolizing	enzymes,	CYP27A1	and	CYP27B1,	
within	 psoriatic	 lesions.9,10	 On	 the	 other	 hand,	 vitamin‑D	
supplementation	and	treatment	with	oral	calcitriol	have	been	
associated	with	clinical	improvement	in	psoriasis	lesions.11‑13
Osteoporosis	is	a	skeletal	disorder	characterized	by	reduced	
bone	mass	and	micro	‑	architectural	changes	in	bone	tissue	
that	 result	 in	 an	 increased	 risk	 of	 fractures.14	 The	 World	
Health	 Organization	 defines	 osteoporosis	 as	 bone	 mineral	
density	<2.5	 standard	deviation	below	 the	mean	 for	 young	
white	 adult	women	 (T‑score).	Osteopenia	 is	 defined	 as	 the	
presence	 of	 a	 bone	 mineral	 density	 between	 1.5	 and	 2.5	
below	the	T‑score	and	represents	a	low	bone	mass	that	is	not	
as	severe	as	osteoporosis.	This	entity	is	a	major	public	health	
problem	due	to	the	increased	risk	of	development	of	fractures	
associated	 with	 osteoporosis.15	 However,	 there	 is	 another	
type	 of	 osteoporosis	 that	 can	 occur	 secondary	 to	 various	
entities	such	as	endocrine	pathology,	rheumatologic	disease,	
increased	chronic	 inflammation	and	vitamin‑D	deficiency.16	
In	addition,	the	presence	of	a	lower	bone	mineral	density	has	
been	described	in	patients	with	long‑term	psoriasis	in	a	study	
without	a	control	group.17
Considering	 this	 background,	 a	 cross‑sectional	 study	 with	
a	control	group	was	conducted	 to	assess	 the	 levels	of	bone	
mineral	 density	 in	 patients	 with	 psoriasis	 in	 comparision	
to	 those	 existing	 in	 healthy	 controls	 and	 patients	 without	
psoriasis	diagnosed	with	osteopenia	or	osteoporosis.
Methods
Patients	 with	moderate	 to	 severe	 cutaneous	 psoriasis	 were	
systematically	 recruited	 from	 the	 outpatient	 department	 of	
the	Psoriasis	Unit	of	our	hospital.	Inclusion	criteria	were:	a	
clinical	diagnosis	of	psoriasis	with	a	Psoriasis	Area	Severity	
Index	 higher	 than	 4,	 age	 18	 years	 or	 older,	 residence	 in	
the	 metropolitan	 area	 of	 Granada	 (southern	 Spain)	 and	
adequate	daily	sun	exposure,	described	as	staying	outdoors	
for	at	least	1	hour	per	day.	Exclusion	criteria	were:	personal	
history	 of	 treatment	 with	 systemic	 or	 biologic	 agents,	 or	
photochemotherapy,	 personal	 history	 of	 psoriatic	 arthritis,	
rheumatoid	 arthritis,	 inflammatory	 bowel	 disease	 or	 other	
inflammatory	 diseases	 and	 intake	 of	 calcium	 or	 vitamin‑D	
supplements.	 Moreover,	 healthy	 controls	 from	 the	 same	
metropolitan	 area	 and	 patients	 diagnosed	 with	 osteopenia	
or	 osteoporosis	 who	 were	 followed	 in	 the	 Endocrinology	
Unit	 of	 our	 hospital	 were	 included	 in	 the	 study.	 All	
the	 osteopenia/osteoporosis	 patients	 had	 been	 recently	
diagnosed	 by	 densitometry	 and	 had	 not	 received	 any	 kind	
of	 treatment.	 Patients	who	met	 these	 selection	 criteria	 and	
signed	an	informed	consent	(in	accordance	with	the	Helsinki	
Declaration)	were	enrolled	in	the	study;	no	selected	patients	
refused	to	participate.	The	study	was	approved	by	the	Ethics	
Committee	of	Hospital	Universitario	Virgen	de	 las	Nieves,	
Granada,	Spain.
Clinical and laboratory parameters
Data	 regarding	 age	 and	 sex	 were	 collected	 from	 all	 study	
participants.	 All	 patients	 underwent	 physical	 examination,	
and	their	weight	and	height	were	recorded	to	calculate	their	
body	 mass	 index	 (kg/m2),	 as	 well	 as	 their	 psoriasis	 area	
and	severity	 index.	Blood	samples	were	drawn	in	 the	early	
morning	for	 laboratory	analysis	of	biochemical	parameters,	
including	 serum	 25(OH)	 vitamin‑D,	 calcium,	 phosphorus,	
parathyroid	 hormone	 and	 osteocalcin.	 In	 addition,	 bone	
mineral	 density	was	measured	by	 bone	densitometry	 using	
dual‑energy	 X‑ray	 absorptiometry,	 employing	 an	 Hologic	
Discovery	Wi®	 (Hologic	 Inc.,	 USA).T‑score	 values	 in	 the	
Ward	 triangle	 of	 the	Hip	 (tHip),	 the	 fourth	 vertebra	 in	 the	
lumbar	spine	(tl4)	and	the	whole	 lumbar	spine	(tl1‑4)	were	
obtained.	All	 laboratory	 parameters	 were	 collected	 in	 two	
consecutive	months	(March/April	2016).
Statistical analysis
A	 descriptive	 analysis	 by	 group,	 psoriasis	 (P),	 control	 (C)	
and	 osteopenia/osteoporosis	 (O),	 was	 carried	 out	 for	 all	
the	 variables	 in	 database.	 Contingency	 tables	 according	
to	 group	 and	 sex	were	made	 using	 generalization	 of	 exact	
Fisher’s	test	in	RXC	tables	to	assess	the	association	between	
them.	One‑way	analysis	of	variance	was	performed	for	each	
numerical	variable	to	compare	means	by	group	and	stratified	
by	sex.	Correlation	matrix	between	numerical	variables	was	
computed	to	measure	the	association	between	them.
To	measure	mean	differences	between	P–C	and	P–O,	multiple	
linear	 regression	 was	 computed.	 Given	 that	 differences	
between	 groups	 were	 affected	 by	 confounding	 factors	
(sex,	body	mass	index,	vitamin‑D,	parathyroid	hormone	and	
osteocalcin),	 a	 crude	 and	 an	 adjusted	model	 are	 presented,	
the	 latter	 being	 the	 main	 analysis	 of	 the	 study.	 This	 type	
of	 analysis	 allows	 the	 elimination	 of	 existing	 differences	
between	the	various	study	groups.	The	outcomes	considered	
were	tHip	and	tl4,	and	covariates	were	group,	sex,	body	mass	
index,	vitamin	D,	parathyroid	hormone	and	osteocalcin.
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Fore	 statistical	 analysis,	 STATA	 14.1	 (Statacorp,	 College	
Station,	Texas,	EEUU)	was	used.
Results
The	 final	 study	 sample	 of	 185	 patients	 comprised	 three	
groups	 –	 the	 psoriasis	 group	 (P	 group)	 with	 58	 patients	
[33	 males	 and	 25	 females,	 Table	 1],	 the	 control	 group	
(C	group)	with	61	patients	(19	male	and	42	female)	and	the	
osteopenia/osteoporosis	 group	 (O	 group)	 with	 67	 patients	
(16	male	and	51	female).	The	three	groups	[Table	2]	differed	
in	the	number	of	males	and	females	included	in	each	group	
(P	 <	 0.001);	 however,	 no	 differences	were	 found	 in	mean	
age	(P	group:	48.88	±	14.04;	C	group:	51.80	±	10.33;	O	group:	
51.88	±	12.27; P =	0.315).	Body	mass	 index	was	 found	 to	
be	higher	in P group	than	the	other	groups	(P:	30.34	±	6.50;	
C:	 26.10	 ±	 3.25;	 O:	 25.22	 ±	 3.94; P <	 0.001).	Moreover,	
vitamin‑D	levels	were	lower	in	P	group	in	relation	to	the	other	
groups	(P	<	0.001).	In	addition,	differences	in	the	parathyroid	
hormone	means	were	found,	showing	upper	levels	in	the	O	
group	with	respect	to	the	other	two	groups	(P	=	0.018)	and	
higher	 osteocalcin	 levels	 in	 the	 P	 and	O	 groups	 compared	
to	 the	C	 group	 (P	 =	 0.002).	 Finally,	 the	 crude	 comparison	
of	 means	 concerning	 the	 outcomes	 tHip	 and	 tl4	 showed	
significative	 differences	 (P	 <	 0.001)	 between	 different	
groups.	 These	 statistical	 differences	 remained	 stable	 after	
stratification	by	sex	[Table	3].
The	multiple	 linear	 regression	 for	 hip	T‑score	 adjusted	 for	
confounding	 factors,	 including	 sex,	 age,	 body	mass	 index,	
vitamin‑D,	parathyroid	hormone	and	osteocalcin	 [Table	4],	
showed	that	the	mean	hip	T‑score	in	group	C	was	higher	than	
group	P	(P	=	0.001),	whereas	the	average	T‑score	in	the	O	group	
was	lower	than	P	group,	not	reaching	statistical	significance	
(P	 =	 0.129).	 Furthermore,	 age	 showed	 an	 independent	
effect	on	the	levels	of	hip	T‑score,	decreasing	its	value	with	
the	 increased	age	of	patients	 (P	=	0.001).	Furthermore,	 the	
body	mass	index	variable	also	showed	a	significant	effect	on	
hip	T‑score,	 increasing	 its	 value	with	 the	 body	mass	 index	
rising	[r	=	0.272; P =	0.035,	Figure	1].	On	the	contrary,	an	
inverse	association	between	hip	T‑score	and	Psoriasis	Area	
Severity	 Indexwas	 found,	 although	 this	 association	 was	
nearly	 significant	 [r=	 −0.230; P =	 0.091,	 Figure	 2].	 The	
variables	 such	 as	 gender,	 vitamin‑D,	 parathyroid	 hormone	
and	 osteocalcin	 did	 not	 show	 any	 significant	 effect	 on	 hip	
T‑score.
The	 multiple	 linear	 regression	 for	 L4	 T‑score	 adjusted	 for	
confounding	factors	[Table	5]	revealed	that	the	average	T‑score	
in	C	was	higher	than P (P	=	0.002),	while	the	mean	T‑score	
in	O	was	significantly	lower	than	P (P	<	0.001).	None	of	the	
other	variables	showed	a	significant	effect	on	L4	T‑score.
Discussion
General data
In	 this	 study,	 bone	mineral	 density	 values	 in	 patients	with	
psoriasis	 were	 significantly	 lower	 than	 in	 healthy	 controls	
from	the	general	population.	In	addition,	a	trend	was	observed	
in	psoriasis	patients,	who	presented	with	better	levels	of	bone	
mineral	 density	 than	 patients	 of	 osteopenia/osteoporosis.	
Significant	differences	between	group	P	and	group	O	were	
only	 observed	 in	 the	 T‑score	 of	 L4	 after	 adjustment	 for	
confounding	factors.
Table 1: General characteristics of the basal features of the 
psoriatic patients included on the study
Variables Mean and standard deviation 
or number and percentage
Age 48±14.05
Gender	(%)
Male 33	(56.9)
Female 25	(43.1)
PASI 7.016±5.08
Time	of	evolution	(years) 12.20±6.14
BMI 30.54±6.50
BMI: Body Mass Index, PASI: Psoriasis Area Severity Index
Table 2: General comparison of the basal characteristics 
among the three study groups
Psoriasis Control Osteopenia p
Age 48,87±14,05 51,80±10,33 51,88±12,27 0,315
Sex 0,001
M 33 19 16
F 25 42 51
BMI 30,34±6,50 26,10±3,25 25,22±3,94 <0,001
VitD	ƪ 19,29±7,86 28,08+/7,16 28,93±10,18 <0,001
PTH	Ʈ 47,00±17,61 45,61±14,97 53,81±18,92 0,018
Osteoc	Ʋ 18,83±7,10 14,58±5,04 18,72±8,76 0,002
tHip	Ʃ ‑0,630±0,962 ‑0,078±0,852 ‑1,206±0,779 <0,001
tl4	Ɵ ‑1,443±4,701 ‑0,098±0,732 ‑2,273±0,724 <0,001
 ƪ Vitamin‑D; ƪ Parathyroid hormone; ƪ Osteocalcin; ƪ Hip T‑Score; ƪ L4 
T‑Score. Hip T‑Score and L4 T‑Score values reflect number of standard 
deviations of the bone mineral density with respect to the average value of the 
population of 20 to 39 years of the same sex Figure 1:	Correlation	between	body	mass	index	and	hip	T‑score	(r	=	0.272)
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Although	not	 related	 to	 the	primary	objective	of	 the	 study,	
some	 of	 the	 current	 results	 deserve	 comment.	 First,	 in	 the	
psoriatic	 group	 the	 percentage	 of	 men	was	 slightly	 higher	
than	women	 (56.9%	vs	43.1%),	while	 in	 the	control	group	
and	osteoporosis	group	the	percentage	of	women	was	higher	
(68.9	and	76.1%,	respectively).	These	results	are	consistent	
with	the	findings	of	a	recent	American	review18	and	another	
study	 carried	 out	 in	 Spanish	 population.19	On	 the	 contrary,	
the	high	percentage	of	women	 in	 the	O	group	 is	 similar	 to	
that	found	in	other	epidemiological	studies	in	industrialized	
countries.20,21	Likewise,	a	higher	body	mass	index	in	psoriatic	
patients	 has	 also	 been	 described.22	 In	 addition,	 previous	
studies	 have	 demonstrated	 that	 increased	 body	mass	 index	
was	positively	correlated	with	 increased	 risk	of	developing	
psoriasis.23,24
Relationship between psoriasis and lower levels of bone mineral 
density
In	 our	 study,	 we	 have	 observed	 lower	 levels	 of	 bone	
mineral	density	in	patients	with	psoriasis	as	compared	to	
healthy	 controls.	There	 are	 several	 studies	 that	 reinforce	
the	 idea	of	 the	association	of	psoriasis	with	 lower	 levels	
of	 bone	 mineral	 density.	 A	 recent	 cross‑sectional	 study	
without	control	group	performed	in	patients	with	psoriasis	
and	 psoriatic	 arthritis	 showed	 that	 63%	 of	 patients	 had	
deficient	levels	of	vitamin‑D,	which	is	inversely	correlated	
with	 body	 mass	 index	 of	 patients.25	 In	 addition,	 in	 this	
study	no	significant	association	between	vitamin‑D	levels	
and	bone	mineral	density	was	 found,	which	 is	consistent	
with	 our	 findings.	 In	 2011,	Attiaet al.	 demonstrated	 that	
patients	 with	 psoriasis	 and/or	 psoriatic	 arthritis	 showed	
worse	 bone	 mineral	 density	 levels	 relative	 to	 healthy	
Table 3: General comparison of the basal characteristics among the three study groups stratified by sex
Variables Male Female
Psoriasis Control Osteoporosis P Psoriasis Control Osteoporosis P
Age 47.91±11.02 50.85±9.85 50.68±10.92 0.291 50.18±15.23 52.44±10.98 52.65±11.08 0.428
BMI 31.28±8.28 26.40±4.21 26.04±3.83 <0.001 29.42±7.31 25.92±3.45 24.98±4.32 <0.001
Vitamin	D 20.03±7.45 28.35±7.33 29.14±8.04 <0.001 18.98±8.30 27.46±7.82 28.04±7.21 <0.001
PTH 47.80±18.45 46.52±15.28 52.25±17.21 0.041 46.10±17.22 45.14±14.49 54.12±19.06 0.024
Osteocalcin 18.68±7.22 14.16±5.42 18.54±6.82 0.032 18.97±8.34 14.82±6.09 18.86±7.04 0.016
tHip −0.545±0.842 0.032±0.721 −1.145±0.842 <0.001 −0.702±0.823 −0.144±0.842 −1.296±0.722 <0.001
tl4 −1.338±4.682 0.009±0.635 −2.105±0.773 <0.001 −1.526±4.971 −0.178±0.801 −2.342±0.823 <0.001
tl1‑4 −1.294±3.647 0.066±0.834 −2.099±0.745 <0.001 −1.472±4.122 −0.109±0.769 −2.301±0.797 <0.001
BMI: Body mass index, tHip: Triangle of the Hip, tl4: Fourth vertebra in the lumbar spine, tl1‑4: The hole lumbar spine, PTH: Parathyroid hormone
Figure 2:	Correlation	between	psoriasis	area	severity	index	and	hip	T‑score	
(r	=	−0.230)
Table 4: Crude and adjusted for confounding factors regression model in the comparisons of triangle of the hip levels between 
psoriasis and control group and psoriasis and osteopenia/osteoporosis group
Variables Crude model Adjusted model
Coefficient 95% CI P Coefficient 95% CI P
P‑C 0.551 0.283	to	0.865 0.001 0.679 0.272	to	1.086 0.001
P‑O −0.576 −0.883	to−0.269 <0.001 −0.307 −0.704	to	0.091 0.129
M‑F −0.276 −0.883	to−0.269 0.065 −0.049 −0.359	to	0.260 0.753
Age −0.012 −0.024	to−0.001 0.036 −0.049 −0.359	to−0.009 0.001
BMI 0.033 0.004	to	0.061 0.025 0.034 0.002	to	0.065 0.035
Vitamin‑D −0.004 −0.019	to	0.011 0.629 0.000 −0.015	to	0.016 0.954
PTH −0.009 −0.017	to−0.001 0.027 0.000 −0.009	to	0.008 0.947
Osteocalcin −0.026 −0.045	to−0.007 0.007 −0.006 −0.025	to	0.013 0.546
Coefficient reflects the differences in the mean values of the bone mineral density in the P‑C, P‑O and M‑F comparisons (adjusted for the other variables in the 
adjusted model) and the increase or decrease of the bone mineral density regarding the other variables in the other lines (adjusted for confounding factors in the 
adjusted model). BMI: Body mass index, PTH: Parathyroid hormone, P‑C: Psoriasis/control relationship, P‑O: Psoriasis‑osteopenia/osteoporosis relationship, 
M‑F: Male/female relationship, CI: Confidence interval
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controls.26	Similar	results	have	been	recently	published	in	
a	 study	performed	 in	Turkish	population.27	 In	 this	paper,	
the	 presence	 of	 lower	 levels	 of	 bone	 mineral	 density	
in	 women	 with	 psoriasis	 relative	 to	 healthy	 controls	
is	 described,	 while	 no	 differences	 were	 found	 in	 the	
comparison	between	men.	However,	both	these	studies	did	
not	perform	an	adjustment	for	possible	confounders	such	
as	body	mass	index	or	age.
An	inverse	association	between	body	mass	index	and	serum	
levels	 of	 vitamin	 D	 have	 been	 demonstrated	 by	 several	
studies,	both	in	patients	with	psoriasis7,25	and	in	healthy	and	
obese	patients.28‑30
Correlation between body mass index and bone mineral 
density
This	possible	association	between	the	two	parameters	could	
suggest	 that	 patients	 with	 psoriasis	 and	 high	 body	 mass	
index	 have	 lower	 levels	 of	 bone	 mineral	 density	 at	 the	
expense	 of	 reduced	 serum	 levels	 of	 vitamin‑D.	 However,	
in	our	study	we	have	found	a	positive	association	between	
body	mass	index	and	hip	T‑score	in	patients	with	psoriasis.	
These	results	are	consistent	with	other	publications,	in	which	
it	 is	 described	 that	 a	 low	body	mass	 index	correlates	with	
lower	bone	mineral	density	in	postmenopausal	women.31	In	
2011,	Pedreiraet al.	conducted	a	cross‑sectional	study	with	
a	control	group,	comparing	the	association	of	bone	mineral	
density	 levels	 with	 various	 anthropometric	 parameters	 in	
patients	with	psoriasis.32	In	this	paper,	a	positive	correlation	
between	 bone	 mineral	 density	 and	 body	 mass	 index	 was	
observed.	 Recently,	 Honmaet al.	 have	 reported	 a	 similar	
positive	 correlation	 in	 psoriatic	 patients.33	 In	 addition,	
Skrzek	 et al.	 have	 determined	 that	 the	 risk	 of	 developing	
osteopenia/osteoporosis	in	postmenopausal	women	is	lower	
in	 those	with	 a	 body	mass	 index	of	 26–27.9.34	Thus,	 after	
adjustment	 for	 confounding	 factors,	 the	 high	 body	 mass	
index	 present	 in	 patients	with	 psoriasis	 appears	 to	 protect	
these	patients	against	osteopenia/osteoporosis,	mitigating	the	
negative	effect	on	bone	mineral	density	produced	by	chronic	
inflammation	and	 low	 levels	of	vitamin	D	present	 therein.	
This	 protective	 effect	 is	 particularly	 evident	 by	 observing	
the	 lower	 difference	 in	 bone	mineral	 density	 between	 the	
psoriatic	group	and	the	osteopenia/osteoporosis	group	after	
the	adjustment.
The	association	between	psoriasis	and	chronic	inflammation	
has	 been	 extensively	 described	 in	 literature,	 being	 one	 of	
the	 most	 common	 immune‑mediated	 inflammatory	 skin	
disorders.35	This	 increase	 in	 systemic	chronic	 inflammation	
has	also	been	related	with	lower	vitamin‑D	and	bone	mineral	
density	levels.7,17
Limitations and need for future studies
The	 limitations	 of	 this	 study	 are	 those	 of	 cross‑sectional	
studies	with	control	group,	such	as	the	lack	of	follow	up	and	
the	inability	of	making	causality	inferences.	Although	there	is	
a	male	predominance	in	the P group,	the	use	of	a	multivariate	
analysis	 with	 adjusted	 model	 eliminates	 the	 differences	
between	the	study	groups	mediated	by	this	variable,	making	
the	 groups	 fully	 comparable.	 On	 the	 contrary,	 despite	 the	
multiple	studies	describingthe	association	between	psoriasis	
and	 low	 bone	 mineral	 density	 levels,	 a	 recent	 Norwegian	
population‑based	study	has	not	found	a	reduced	bone	mineral	
density	level	or	an	increased	risk	of	osteoporosis	in	psoriatic	
patients.36	Moreover,	despite	the	deficit	of	vitamin	D	found	
in	patients	with	psoriasis,	 treatment	with	oral	 calcium	and/
or	 vitamin	 D	 to	 prevent	 osteoporotic	 fractures	 remains	
controversial.37,38
Conclusions
In	 conclusion,	 a	 cross‑sectional	 study	 comparing	 bone	
mineral	 density	 in	 psoriatic	 patients	 vshealthy	 controls	
and	patients	with	osteopenia/osteoporosis	is	presented.	We	
were	 unable	 to	find	 any	 report	 of	 the	 last	 comparison	 in	
literature.	According	to	our	results,	levels	of	bone	mineral	
density	 in	 patients	with	moderate	 to	 severe	 psoriasis	 are	
situated	halfway	between	those	present	in	healthy	controls	
and	 patients	 with	 osteopenia/osteoporosis.	 The	 higher	
body	mass	 index	found	 in	 the	psoriatic	group	could	be	a	
protective	 factor	 against	 the	 development	 of	 osteopenia/
osteoporosis	 in	 these	 patients.	 However,	 more	 studies	
would	 be	 needed	 to	 demonstrate	 a	 causal	 association	
Table 5: Crude and adjusted for the confounding factors regression model in the comparison of fourth vertebra in the lumbar 
spine levels between psoriasis and control group and psoriasis and osteopenia/osteoporosis group
Variables Crude model Adjusted model
Coefficient CI (95%) P Coefficient CI (95%) P
P‑C 1.346 0.373	to	2.319 0.007 0.860 0.320	to	1.400 0.002
P‑O −0.829 −1.781	to	0.123 0.087 −1.185 −1.709	to	−0.661 <0.001
M‑F −0.570 −1.417	to	0.278 0.186 −0.096 −0.508	to	0.317 0.648
Age −0.024 −0.057	to	0.010 0.163 0.002 −0.015	to	0.018 0.826
BMI 0.052 −0.033	to	0.060 0.233 0.020 −0.022	to	0.061 0.353
Vitamin‑D 0.014 −0.032	to	0.060 0.553 0.004 −0.017	to	0.025 0.733
PTH −0.014 −0.037	to	0.010 0.259 −0.005 −0.017	to	0.007 0.408
Osteocalcin −0.061 −0.088	to	−0.034 0.007 −0.026 −0.052	to	0.000 0.052
BMI: Body mass index, PTH: Parathyroid hormone, P‑C: Psoriasis/control relationship, P‑O: Psoriasis‑osteopenia/osteoporosis relationship, M‑F: Male/female 
relationship, CI: Confidence interval
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between	psoriasis	and	 the	 risk	of	developing	osteopenia/
osteoporosis.
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